C-DQNFBloom Science
live biotherapeutics, gut-brain axis, ketogenic biology
modulatingmicrobiome therapeutic
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
←All companiesC-DQNF
C-DQNFC-DQNFlive biotherapeutics, gut-brain axis, ketogenic biology
0-100 chain-logic scale · 15 dimensions · scored on public evidence
To investigate the safety and tolerability of BL-001 in healthy volunteers for 28 consecutive days.
CERF 2019 Sessions Schedule: Tuesday Member Login Search CERF 2019 CERF 2019 Updates About the Conference Theme CERF 2019 Conference Artist Conference Committees Family Friendliness at CERF 2019 Safe and Welcoming CERF Event Code of Conduct CERF 2019 Scientific Awards About the Awards Scientific Awards Recipients CERF 2019 Policies CERF 2019 Media Toolkit CERF 2019 Press Program Post-Conference Resources Schedule-at-a-Glance Monday Sessions Tuesday Sessions Wednesday Sessions Thursday Sessions Keynote Plenary Sessions Workshops Analyzing, Synthesizing, and Communicating Your Data Beginner GIS
Instagram See everyday moments from your close friends . Log into Instagram Mobile number, username or email Password Log in Forgot password? Log in with Facebook Create new account Meta About Blog Jobs Help API Privacy Terms Locations Popular Instagram Lite Meta AI Threads Contact Uploading & Non-Users Meta Verified English Down chevron icon Afrikaans العربية Čeština Dansk Deutsch Ελληνικά English English (UK) Español (España) Español فارسی Suomi Français עברית Bahasa Indonesia Italiano 日本語 한국어 Bahasa Melayu Norsk Nederlands Polski Português (Brasil) Português (Portugal) Русский Svenska ภ
Licensing Deals in Biotechnology 2020-2026 - Research and Markets Your browser is not supported. To avoid security issues and to comply with web standards, please upgrade to a modern browser. ABOUT US CONTACT US FAQ  USD EUR GBP USD ▼ USD EUR GBP € EUR $ USD £ GBP +353-1-416-8900 REST OF WORLD +44-20-3973-8888 REST OF WORLD 1-917-300-0470 EAST COAST U.S 1-800-526-8630 U.S. (TOLL FREE)  Login / Register Contact Us About Us View Categories Our Services Our Services Back Market Research Custom Research Conferences & Training Subscription … rvice CRADA Cross-licensing Development Distribution Equity purchase Evaluation Grant Joint venture Licensing Loan Manufacturing Marketing Option Promotion Research Royalty financing Settlement Spin out Sub license Supply Termination Warrant Every deal record is fully categorized and includes the following data, where available: Industry sector Therapy areas Technology type Deal components Financial terms Stage of development Exclusivity Asset type Geographic focus Excluded g … Forecasts, Till 2035 - Distribution by Source of Cell Line / Expression System, Application of Cell Line, Company Size, and Key Geographical Regions  Report 455 Pages December 2025 Global From €4311 EUR $4,799 USD £3,730 GBP This product is a market research report. Each license type allows a set number of users to access the report. Please select an option from the list below. This product is a market research report. This is a single user license, allowing one user … ng Deals in Biotechnology 2020-2026 close close ASK A QUESTION RESERVE MY PLACE Submit the form to confirm your enrolment and receive payment instructions. An error occurred while sending the message. Should this issue persist, email us at [email protected] * Required Information Name * Mr Mrs Dr Miss Ms Prof { }..." data-val-regex-pattern="^[^<>{}]*$" data-val-required="First Name field is required!" id="ProductEnquiry_FirstName" maxlength="50" name="ProductEnqu
%PDF-1.3 %��������� 5 0 obj > stream x+TT(T0BSKS=#s3 C= K��T�p� > endobj 7 0 obj > >> endobj 8 0 obj > >> stream x��K�lK�$6�U�2*��1. K8,�A/�IWs�ה� p�T|T�� W�|9H\;f ��~���� ����]�������q9~>�?����o ���_�������%>ϗ�����_���e���ǿ��?� �� �8~� ���q�}~��?�������u� � ���x���:].M� ?�(r e�? �¢\uc���_ ��q�� ����|?]/����q9 ?��_g[�T�9(Ȟ���/ׯ�G�s9 �+�9�l��=�����>����q:_���7z;jF�Cޒ���N���qCK��[@���:��߉K � � $�Dr��9 YZ�@_�gn��{ �F�` ��hW ��=8; �)qj�}#�V�]��0���1z �s9�Չ6[���+��2 mTm �b�O�z�g���bI �R�^ ��e,cu�Ό�䷰�-�i�_�/�K{PQ�-��p��_���&�� ݒ�W9h�����,�v�Eg��?�� �HS���oHm … Pi�hN�z����QS��$g�m� �`� ��>�P� ��t���jO��b#��,��,$�+|�7�1T^#S:�ɣ�~[�x��rfp����������%����9n�{�e�-%�P�dYuCʂ��vN �qCs1vB��Ty!ϖ�5tN 7z�-C5��������џ�Q�l� �c`s��� ��Hz�Y ��3 �{��&�;��o1����Z� e|9R���?��?���D�.Z*֙At�I�?BE���t��[�O��"Oy�]ۡJ?�8 ʋ� -�hu�Nm����~��Cf8=)�Z�U3��B�-��Q��HS"Zk�j�[�����1 �+���A�]�E�^`���Ă�� ��8���Cu4?���k�� I�u��ƪ�}�&�j�v��EZ��,)��%8�#h�&�j}#[�b�5�^��> I��S�K�Cemޒ���Z� ���>��֚e䪣��5���=�1 �d�C�E��U�Cuj}$����Z ����H:��ù �Y��S … ����ս i�'�{���_��d\*h�)�U���&��x��F��%4��� @��� �QZ��R�6V1���k�=���ӹ`�RfP � ]G�{�Ur��u���֎�Bs#�?>7v�!���M(��� ��h��r���G ����f�l��� w`���9�V� xj^��^! hk�gA ��`���O7u� � $;iӭ���U�N[�b 1��9�Ɖ)�, '_� ,Y`�|�R�K��+�&lQ�gyш/ߧ;|�B�����VG�H���I71�Ӊ����ҧ_ Eua�oq����rG��dS�>(a��GC��%� �p.!p�H��� -�;m1�(v��B���撞@ιF��cާ�P\��MY�n���fF��� �{������&����Q 4������y����0��撖3���{�0��ץܥ�(s����(ō�*�31���}:5�B6���: b5�����G�?w@��ާ�(�Z,6�`� h��
Obesity Today—March 3, 2026 - LucidQuest Ventures Consulting Services Strategic and Tactical Competitive Insights across Therapy Areas Digital Health, Artificial Intelligence & Internet of Everything Gene & Cell Therapy, Rare Diseases Vaccines & Infectious Diseases For Investors Investor Diligence and Decision Support Lucid Diligence Briefs Venture Capital Trends Products LucidWargames (HITL AI-powered workshops) LucidScope (AI Answer Intelligence) QuickAnswers (Rapid Primary Research) LucidSearch (BioPharma-dedicated Search Engine) Case Studies Insights LucidWargames Conference … re data for setmelanotide in acquired hypothalamic obesity and said it plans to submit the final data package to FDA on 02 Mar 2026. Implication: May influence prescriber choice and payer reviews pending full data. 🤝 Pfizer China adds Sciwind Biosciences as partner for ecnoglutide commercialization [5] [China • 24 Feb 2026] https://www.forbes.com/sites/russellflannery/2026/02/24/pfizer-adds-sciwind-as-china-partner-for-new-weight-loss-drug/ Context: Collaboration framed as C … nt: BioWorld reported China’s NMPA accepted Jiuyuan Genetic Biopharmaceutical’s application for Jikeqin, described as a biosimilar to Novo Nordisk’s Wegovy (semaglutide) for obesity. Implication: Introduces competition that may affect pricing and formulary access. 📄 Sam Chun Dang Pharm cites Europe deal for “oral Wegovy” positioning [10] [EU • 27 Feb 2026] https://biz.chosun.com/en/en-finance/2026/02/27/XPQNY7JKOVFS5EH42THK2CVBUM/ Context: Deal described as a technology tran … pted for review” matter? BioWorld reported that China’s NMPA accepted Jiuyuan’s application for review for a Wegovy (semaglutide) biosimilar. Acceptance signals the dossier has entered the agency’s review process, not that approval is granted. [9] Entities / Keywords knownwell (hybrid obesity care, metabolic health clinic model, real-world outcomes) Bloom Science (BL-001, live biotherapeutic product, ketogenic biology, Phase 1b) Novo Nordisk (UBT251 partnership, Vivtex oral d
tm2611464-4_nonfiling - block - 6.7067161s TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ​ SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.  ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ​ ☐ Preliminary Proxy Statement ​ ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ​ ​ ☒ Definitive Proxy Statement ​ ☐ Definiti … ment, if other than the Registrant) Payment of Filing Fee (Check all boxes that apply): ☒ No fee required ​ ☐ Fee paid previously with preliminary materials ​ ☐ Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(I)(1) and 0-11 ​ TABLE OF CONTENTS   Voyager Therapeutics, Inc. 75 Hayden Avenue Lexington, MA 02421 NOTICE OF 2026 ANNUAL MEETING OF STOCKHOLDERS ​       … areholdermeeting.com/VYGR2026 where you will be able to vote electronically and submit questions. You will need the 16-digit control number located on the Notice, as described below, to vote at the Annual Meeting .   ​ Stockholders of record at the close of business on April 13, 2026, the record date for the Annual Meeting, are entitled to notice of, and to vote at, the Annual Meeting or any adjournment or postponement of the Annual Meeting. The purpose of th … HE MEETING AND VOTING ​ ​ ​ ​ 2 ​ ​ ​ PROPOSAL 1 ELECTION OF DIRECTORS ​ ​ ​ ​ 7 ​ ​ ​ CORPORATE GOVERNANCE ​ ​ ​ ​ 12 ​ ​ ​ DIRECTOR COMPENSATION ​ ​ ​ ​ 21 ​ ​ ​ EXECUTIVE OFFICERS ​ ​ ​ ​ 24 ​ ​ ​ EXECUTIVE COMPENSATION ​ ​ ​ ​ 26 ​ R … ECUTIVE COMPENSATION ​ ​ ​ ​ 26 ​ ​ ​ PROPOSAL 2 ADVISORY VOTE ON NAMED EXECUTIVE OFFICER COMPENSATION ​ ​ ​ ​ 44 ​ ​ ​ PROPOSAL 3 RATIFICATION OF APPOINTMENT OF INDEPENDENT AUDITORS ​ ​ ​ ​ 45 ​ ​ ​ PROPOSAL 4 APPROVAL OF
Licensing Deals in Biotechnology 2020-2026 - Research and Markets Your browser is not supported. To avoid security issues and to comply with web standards, please upgrade to a modern browser. ABOUT US CONTACT US FAQ  USD EUR GBP USD ▼ USD EUR GBP € EUR $ USD £ GBP +353-1-416-8900 REST OF WORLD +44-20-3973-8888 REST OF WORLD 1-917-300-0470 EAST COAST U.S 1-800-526-8630 U.S. (TOLL FREE)  Login / Register Contact Us About Us View Categories Our Services Our Services Back Market Research Custom Research Conferences & Training Subscription … rvice CRADA Cross-licensing Development Distribution Equity purchase Evaluation Grant Joint venture Licensing Loan Manufacturing Marketing Option Promotion Research Royalty financing Settlement Spin out Sub license Supply Termination Warrant Every deal record is fully categorized and includes the following data, where available: Industry sector Therapy areas Technology type Deal components Financial terms Stage of development Exclusivity Asset type Geographic focus Excluded g … Forecasts, Till 2035 - Distribution by Source of Cell Line / Expression System, Application of Cell Line, Company Size, and Key Geographical Regions  Report 455 Pages December 2025 Global From €4311 EUR $4,799 USD £3,730 GBP This product is a market research report. Each license type allows a set number of users to access the report. Please select an option from the list below. This product is a market research report. This is a single user license, allowing one user … ng Deals in Biotechnology 2020-2026 close close ASK A QUESTION RESERVE MY PLACE Submit the form to confirm your enrolment and receive payment instructions. An error occurred while sending the message. Should this issue persist, email us at [email protected] * Required Information Name * Mr Mrs Dr Miss Ms Prof { }..." data-val-regex-pattern="^[^<>{}]*$" data-val-required="First Name field is required!" id="ProductEnquiry_FirstName" maxlength="50" name="ProductEnqu
Pipeline - Bloom Science Science & Pipeline Patients People News & Resources Careers Contact Us Pipeline Live Biotherapeutics for Patients with Metabolic and Neurological Disorders Bloom’s robust clinical and discovery programs aim to address unmet medical needs for metabolic health and devastating neurological diseases. Bloom’s programs and research areas include obesity, metabolic disorders, Dravet syndrome, Developmental and Epileptic Encephalopathies (DEEs), Amyotrophic Lateral Sclerosis (ALS), and neurodegenerative and cognitive disorders. Discovery Programs We have two ar
%PDF-1.6 %���� 1 0 obj >/OCGs[11 0 R]>>/Pages 3 0 R/Type/Catalog>> endobj 2 0 obj >stream application/pdf NIF Agenda 2024-01-06T22:53:34+02:00 2024-01-06T22:53:34+02:00 2024-01-06T22:53:34+03:00 Adobe Illustrator 26.5 (Windows) 208 256 JPEG /9j/4AAQSkZJRgABAgEASABIAAD/7QAsUGhvdG9zaG9wIDMuMAA4QklNA+0AAAAAABAASAAAAAEA
AQBIAAAAAQAB/+4ADkFkb2JlAGTAAAAAAf/bAIQABgQEBAUEBgUFBgkGBQYJCwgGBggLDAoKCwoK
DBAMDAwMDAwQDA4PEA8ODBMTFBQTExwbGxscHx8fHx8fHx8fHwEHBwcNDA0YEBAYGhURFRofHx8f
Hx8fHx8fHx8fHx8fHx8fHx8fHx8fHx8fHx8fHx8fHx8fHx8fHx8fHx8fHx8f/8AAEQgBAADQAwER
AAIRAQMRAf/EAaIAAAAHAQEBAQEAAAAAAAA … +̀C����s�9 cN��c�V8����Y�&}z��8�\%f�8 �V�?(�eB���g��/A`k% �?���q�0n�V�*rFP �Xf #gh[g�.rFx= G�8j�|rK�pO�����3�tȖ �"g��i���Ap䌮���d�:LC���9c�b U|�b��LF'a� hrq��34'�� ��� g���B$A�}#� �8�2 �Y�/�ϞhX���s�A�k %s���Οh�qd�._����3"̻ ?N����o W�6��q��0 ,��*�ʋT��� X?�Kq�(]� �a�_k���(5㌓�����kV/� W�q�u�5ae��Y2Θ�T5��v�i��o\p�%�wD%j D���e�a�p/_s���(P�d�z�}Hahz1�(���3�)�3Ⱥ�y���qƚ�Q e- �Za� �8�y�a���W��3�g���- . ���7x���"9#52*p���na�[�̐�r��֎���Z6�z)2
BL-001 Archives - Page 3 of 4 - Bloom Science Science & Pipeline Patients People News & Resources Careers Contact Us Bloom CEO Christopher Reyes, PhD Patriciates on IamBIO podcast Focused on Exploring the Science of the Microbiome by bloomscience | Feb 5, 2025 | In the News SAN DIEGO, Calif., March 12, 2024 — The gut microbiome plays a crucial role in our health. However, there is still much to learn about this complex ecosystem. In today’s IamBIO episode, Bloom’s CEO Chris Reyes joins other experts who tell us where the science is—how much we know, and how much we don’t.  
Jan 27-29, 90+ Exhibitors at PMWC 2027 Silicon Valley Chat with us , powered by LiveChat Skip to content Chats Contact Speakers Agenda Tickets Menu FULL MENU FULL MENU Register here Rates by JUL. 2 Register here PMWC, Jan 25-27, 2023 PMWC - Silicon valley, ca January 27-29, 2027 Past Event PMWC, Feb 5-7, 2025 PMWC - Silicon valley, ca January 27-29, 2027 Attend Program Schedule Sessions Honorees Speakers Company Competition Showcases Travel Venue Sightseeing Reduced Rates Hotel Flights Exhibits + Map Login / My Account Participate REGISTER TO EXHIBIT Prospectus Attendee Breakdown Apply to spea … ogin / My Account Participate Register to Exhibit Prospectus Attendee Breakdown Apply to speak Sponsorship Inquiry GET UPDATES ABOUT Mission Testimonial Past Conferences Past Honorees Past Speakers FAQ CONTACT US Menu agenda speakers exhibits Contact us agenda speakers exhibits Contact us BUY TICKETS SAVE $1351 BY JUL. 2 Menu Item #1 Item #1 PMWC - Silicon valley, ca Jan. 27-29, 2027 Pittsburgh, pa sep. 23-24 PMWC - Silicon valley, ca Jan. 27-29, 2027 Register Here Rates by J … tend Program Speakers Travel Exhibits + Map Main Program View your save program Award Reception Speaker gallery Select part speakers Exhibit gallery Part conferences Participate Register to Exhibit Apply to speak Sponsorship Inquiry ABOUT Login / My Account CONTACT US Get Updates Pittsburgh, pa sep. 23-24 Register Here Rates by Attend Program Travel Reduced Rates Exhibits + Map Main Program View your save program Award Reception Paticipate Register to Exibit Apply to speak Sp … nomix Labs Alphaexpeditions Alpine Alquest Therapeutics ALS Emergency Treatment Fund Alta Bates Summit Comprehensive Cancer Center Alta Devices AltaQ Altered Egos Comics AltheaDx Althia Altiora Altis Biosystems, LLC Altoida Inc Altos Labs AltruBio Altum Medical Alum Alumot – sprint Aluna Health Alva10 Alveo Technologies Alverno Laboratories AlwaysRx Alykomed Global Solutions LLC Alykomedglobal Alzheimer’s X Alzheon AMA Ama-Assn Amaro Therapeutics Amazon Amber Health Amb … Y Ancestry Anderson Cancer Center Andreessen Horowitz Andrew Andy Strouse Angel Fund Angel Investor ANGLE Biosciences ANGLE Europe Ltd. ANGLE, plc Angleplc Angstrom Bio Angular Medicine Anima AnjaGen Consulting Anl Annai Systems, Inc Annexon Biosciences Annexon Inc Annexonbio Anocca Ansun Biopharma Antenna Anthem Anthony Pastena, M.D. ,P.C Anthos
✨ A heartfelt THANK YOU to... - Dravet Syndrome Foundation Facebook Log In Dravet Syndrome Foundation's Post Dravet Syndrome Foundation December 11, 2025 · Shared with Public A heartfelt THANK YOU to our incredible industry partners whose support made our 16th Annual Research Roundtable a resounding success! This important gathering brings together researchers, medical professionals, and industry leaders to share the latest advancements in Dravet syndrome research—and it wouldn’t be possible without your partnership. A special shout-out to our Platinum Sponsor, Stoke Therapeutics, for the
Understanding Algal Blooms: State of the Science Conference | Ohio Sea Grant TOP Understanding Algal Blooms: State of the Science Conference | Ohio Sea Grant We see you are using an outdated browser. Be secure and please upgrade your browser to improve your experience. [ ☰ ] Ohio State University Skip to content The Ohio State University Ohio Sea Grant /news/calendar/2024/09/04/j06wf/state-of-science-conference Help Search Ohio State Toggle navigation CFAES Ohio Sea Grant OSG About Us 100 Years People Partnerships Recognition Jobs Contact Search... About Us About Us 100 Years People Part … s from recent studies and identify important areas of uncertainty. Registration deadline: September 4, 2024 General Registration: $50 Student Registration: $10 This event will be livestreamed. During registration, please select virtual or in-person attendance. Please note, the recording of the event will be shared only with those registered. Register Today If you are interested in earning Ohio EPA Contact Hours for this conference, please complete this form . For media … a.m. Welcome and Morning Introductions Christopher Winslow, Director, Ohio Sea Grant & Stone Laboratory, The Ohio State University 9:25 a.m. – 9:30 a.m. Morning Session: From the National to the Local Scale Nutrients and Harmful Algal Blooms ( HAB s): Issues and Actions Across Different Regions of the Country Betty Staugler, National Sea Grant HAB Liaison, Florida Sea Grant 9:30 a.m. – 9:55 a.m. High-Resolution Watershed Modeling to Assess Water Quality Benef … S Resources YOUR RSVP CONTACT Lillyann Nahar Administrative Assistant, Ohio Sea Grant College Program 614-292-1221 YOUR HOSTS Christopher Winslow, PhD Director, Ohio Sea Grant College Program 614-292-8949 View Profile Jay Martin, PhD Professor, OSU Department of Food, Agricultural and Biological Engineering View Profile Asmita Murumkar, PhD Assistant Professor, OSU Extension Agricultural and Natural Resources Program View Profile Greg LaBarge Field Specialist, Agronomic Syste … With Us Newsletter Sign up for our monthly email newsletter , covering Ohio Sea Grant and Stone Lab research, education and outreach . SUBSCRIBE TODAY Help us with our website! Give Feedback Stay Connected Visit our Facebook Page Follow us on Twitter View our Flickr Collection Subscribe to our YouTube Channel Ohio Sea Grant Visit our Facebook Pag
National Office for Algal Bloom Research opens in Adelaide Home What’s Happening? Current News President’s & Political Reports Projects Let’s Fish Australia Positions Vacant Save the Date Membership Member Portal Join AFTA AFTA Tackle Show Trade Days Public Day Exhibitor Portal Future Dates Awards & Recognition Hall of Fame Industry Recognition Product Awards 2025 Awards 2024 Awards 2023 Awards 2022 Awards 2019 Awards 2018 Awards 2017 Awards 2016 Awards 2015 Awards Directories Member Directory Retail Member Directory Wholesale Member Directory Media About Us Meet Our Board AFTA
safety, tolerability, and strain kinetics of bl-001, an orally delivered live biotherapeutic product, in a phase 1 study of healthy volunteers Career Center AES Connect Donate supervisor_account check_circle Get Involved search search Search menu Menu Home Abstracts Abstracts Safety, Tolerability, and Strain Kinetics of BL-001, an Orally Delivered Live Biotherapeutic Product, in a Phase 1 Study of Healthy Volunteers Abstract number : 2.373 Submission category : 7. Anti-seizure Medications / 7B. Clinical Trials Year : 2024 Submission ID : 1056 Source : www.aesnet.org Presentation date : 12/8/20 … ucation arrow_drop_down AES Learn Resident Courses Epilepsy and Neurophysiology Fellowship Match Membership arrow_drop_down Become a Member Get Involved In Memoriam Directory (Members Only) Give arrow_drop_down Make a Gift Planned Giving Your Dollars at Work Targeted Funds Corporate Support About arrow_drop_down About AES Publications & Reports Press Room Reach Members Epilepsy Leadership Council Contact AES arrow_upward Back to top Terms of Use Disclosure P
Facebook Explore the things you love . Log into Facebook Email or mobile number Password Log in Forgot password? Create new account English (US) فارسی العربية Türkçe Deutsch Français (France) Polski More languages… Sign Up Log In Messenger Facebook Lite Video Meta Pay Meta Store Meta Quest Ray-Ban Meta Meta AI Instagram Threads Privacy Policy Privacy Center About Create ad Create Page Developers Careers Cookies Ad choices Terms Help Contact Uploading & Non-Users Meta © 2026
Participating Companies - BIO Investment & Growth Summit 2026 Skip To Main Content February 16-17, 2027 | Miami Beach HOME ABOUT Show submenu for: ABOUT EVENT OVERVIEW WHY ATTEND? FAQS SHARE ON SOCIAL MEDIA CONTACT US SCHEDULE PROGRAM Show submenu for: PROGRAM PROGRAM SPEAKERS ADVISORY COMMITTEE COMPANY PRESENTATIONS PRESENTING COMPANIES BIO Partnering™ Show submenu for: BIO Partnering™ BIO PARTNERING™ PARTICIPATING COMPANIES PARTICIPATING INVESTORS PARTNERING WEBINARS DOWNLOAD THE APP LOG IN TO BIO PARTNERING SPONSOR Show submenu for: SPONSOR Become a Sponsor 2026 Sponsors SEARCH More Sh … equired. Financial, legal, consulting (11) This field is required. Hedge/Mutual Fund (PM,Buy-Side Research) (4) This field is required. Individual Investor (2) This field is required. Institute, hospital research (2) This field is required. Investment bank (12) This field is required. Investor (buy-side or sell-side research) (10) This field is required. IT, information (4) This field is required. Medical device or technology (20) This field is required. Other products or ser … a. Please try again with different keywords or filters. Loading Loading Flip 3i Fund United States Flip Hedge/Mutual Fund (PM,Buy-Side Research) Flip 7 Hills Pharma, Inc. United States Flip Biotech or pharma, therapeutic R&D Flip 8 Prime Biosciences Flip Flip 8VC United States Flip Flip AAA Family Office Israel Flip Family Office Flip AB Science France Flip Biotech or pharma, therapeutic R&D Flip Abbhi Capital Flip Flip Abiozen United States Flip Biotech or pharma, th … ip BoJian Capital United States Flip VC/Corporate VC Flip BOLD Longevity Growth Fund United States Flip VC/Corporate VC Flip Boston Capital Investment Club United States Flip Angel Investing Flip Botanical Solution Inc United States Flip Biotech or pharma, therapeutic R&D Flip Breakthru Medicine's United States Flip Biotech or pharma, therapeutic R&D Flip Bridge United States Flip Other products or services Flip Brighton Capital, Ltd. United States Flip Family Office … rapeutic R&D Flip Fortress Investment Group United States Flip Hedge/Mutual Fund (PM,Buy-Side Research) Flip Forward Equity Partners United States Flip VC/Corporate VC Flip FreeMind Investments United States Flip VC/Corporate VC Flip Frontier Pharma United States Flip Biotech or pharma, therapeutic R&D Flip Fulcrum Therapeutics United Sta
Exhibitor Profile - PMWC Precision Medicine World Conference Chat with us , powered by LiveChat Skip to content Chats Contact Speakers Agenda Tickets Menu FULL MENU FULL MENU Register here Rates by JUL. 2 Register here PMWC, Jan 25-27, 2023 PMWC - Silicon valley, ca January 27-29, 2027 Past Event PMWC, Feb 5-7, 2025 PMWC - Silicon valley, ca January 27-29, 2027 Attend Program Schedule Sessions Honorees Speakers Company Competition Showcases Travel Venue Sightseeing Reduced Rates Hotel Flights Exhibits + Map Login / My Account Participate REGISTER TO EXHIBIT Prospectus Attendee Breakdown Apply … ogin / My Account Participate Register to Exhibit Prospectus Attendee Breakdown Apply to speak Sponsorship Inquiry GET UPDATES ABOUT Mission Testimonial Past Conferences Past Honorees Past Speakers FAQ CONTACT US Menu agenda speakers exhibits Contact us agenda speakers exhibits Contact us BUY TICKETS SAVE $1351 BY JUL. 2 Menu Item #1 Item #1 PMWC - Silicon valley, ca Jan. 27-29, 2027 Pittsburgh, pa sep. 23-24 PMWC - Silicon valley, ca Jan. 27-29, 2027 Register Here Rates by J … tend Program Speakers Travel Exhibits + Map Main Program View your save program Award Reception Speaker gallery Select part speakers Exhibit gallery Part conferences Participate Register to Exhibit Apply to speak Sponsorship Inquiry ABOUT Login / My Account CONTACT US Get Updates Pittsburgh, pa sep. 23-24 Register Here Rates by Attend Program Travel Reduced Rates Exhibits + Map Main Program View your save program Award Reception Paticipate Register to Exibit Apply to speak Sp … nomix Labs Alphaexpeditions Alpine Alquest Therapeutics ALS Emergency Treatment Fund Alta Bates Summit Comprehensive Cancer Center Alta Devices AltaQ Altered Egos Comics AltheaDx Althia Altiora Altis Biosystems, LLC Altoida Inc Altos Labs AltruBio Altum Medical Alum Alumot – sprint Aluna Health Alva10 Alveo Technologies Alverno Laboratories AlwaysRx Alykomed Global Solutions LLC Alykomedglobal Alzheimer’s X Alzheon AMA Ama-Assn Amaro Therapeutics Amazon Amber Health Amb … Y Ancestry Anderson Cancer Center Andreessen Horowitz Andrew Andy Strouse Angel Fund Angel Investor ANGLE Biosciences ANGLE Europe Ltd. ANGLE, plc Angleplc Angstrom Bio Angular Medicine Anima AnjaGen Consulting Anl Annai Systems, Inc Annexon Biosciences Annexon Inc Annexonbio Anocca Ansun Biopharma Antenna Anthem Anthony Pastena, M.D. ,P.C Anthos
Sharon's Ride.Run.Walk. 2026: Bloom Science Skip to main content In order to use BikeSignup, your browser must accept cookies. Otherwise, you will not be able to register for races or use other functionality of the website. However, your browser doesn't appear to allow cookies by default. Click the “Accept Cookie Policy” button below to accept the use of cookies on your browser. If you still see this message after clicking the link, then your browser settings are likely set to not allow cookies. Please try enabling cookies. You can find instructions at https://www.whatismybrowser.com/guid
The Known & the Unknown: Inside Algal Bloom Science – BG Independent News brought to you by Home About Contact News Break Ohio Capital Journal Community Happenings Community Voices Community Opinion Arts and Entertainment Black Swamp Arts Festival Home-1 Education Campus Obituaries Video Story Videos Concert Videos Podcasts Advertise Support Merch Hot Topics June 25, 2026 | As enrollment continues to grow, BGSU works on managing housing, parking and dining demands June 25, 2026 | Bicycle spokespeople: BG recognizes Langendorfer and Kirian for making streets safer for all modes of tra … rmful Algae Blooms Lake Erie Toledo Lake Erie Center Photo courtesy of Ohio Sea Grant Posted By: Tom Gerrow September 25, 2025 By TOM GERROW BG Independent News Harmful Algal Blooms, or HABs, have plagued Lake Erie for decades now. But scientists, government officials and the agricultural industry have been working to understand the nature and causes of HABs, and to reduce their severity. Ohio Sea Grant and Stone Lab co-hosted a recent conference in Toledo to bring these grou … cal confirmation.” The management of agricultural nutrients and the storage and application of manure were also addressed. Samuel Mullins, chief of the Division of Livestock Environmental Permitting at the Ohio Department of Agriculture, provided an overview of the permitting process and operating requirements for large concentrated animal feeding facilities (CAFFs), and major CAFFS (or MCAFFs, which are 10 times larger than CAFFs) in the state. The livestock numbers to quali … le for applying manure. Arnold said that using liquid manure, combined with new application technologies, opens additional windows of opportunity to apply manure. The goal, Arnold said, was to get the right nutrient to the right place, at the right time, and in the right amount. “I was impressed by new technologies and farming practices, such as knifing in manure or using tools such as the Rain 360 Toolbar, which can help farmers get more value from manure while reducing runo … unity Opinion Click typewriter to read opinions from readers or to learn how to submit one of your own. advertise Interested in advertising here on the sidebar of BG Independent News, or in becoming an annual sponsor? Contact Elizabeth Roberts-Zibbel at [email protected] or click image below for the Advertise page, also accessible from the
Bloom Science Raises $11M for Microbiome-Based Weight Loss Therapy | Amir Naiberg posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign i … xcellence. Over the next three years, we’re investing more than $3.5 million to fund 8 new grants across Canada, including: Dr. Tom Appleton ( Western University ) Dr. Robert Inman ( University Health Network ) Dr. Lauren King (@unityhealthtoronto) Dr. Sarah Manske ( University of Calgary ) Dr. Hugo Massé-Alarie ( Université Laval ) Dr. Liam O’Neil ( University of Manitoba ) Dr. Anthony Perruccio ( Schroeder Arthritis Institute ) Dr. Reza Sharif Naeini ( McGill University ) T … hemorrhage control devices in combat and prehospital settings. Funded by a TRC4 grant, this preclinical translational research is driving innovative solutions to transform trauma care and improve survival when every second counts. Learn more about this life-saving research and hear from the Principal Investigator HERE: https://lnkd.in/gCM2WR4i 7 Like Comment Share Copy LinkedIn Facebook X To view or add a comment, sign in Diana Heppe 3mo Report this post As a CF mom, I’ve see
Instagram See everyday moments from your close friends . Log into Instagram Mobile number, username or email Password Log in Forgot password? Log in with Facebook Create new account Meta About Blog Jobs Help API Privacy Terms Locations Popular Instagram Lite Meta AI Threads Contact Uploading & Non-Users Meta Verified English Down chevron icon Afrikaans العربية Čeština Dansk Deutsch Ελληνικά English English (UK) Español (España) Español فارسی Suomi Français עברית Bahasa Indonesia Italiano 日本語 한국어 Bahasa Melayu Norsk Nederlands Polski Português (Brasil) Português (Portugal) Русский Svenska ภ
selection of lead candidate bacteria for bl-001, a live biotherapeutic product in development for the treatment of neurological indications Career Center AES Connect Donate supervisor_account check_circle Get Involved search search Search menu Menu Home Abstracts Abstracts Selection of Lead Candidate Bacteria for BL-001, a Live Biotherapeutic Product in Development for the Treatment of Neurological Indications Abstract number : 2.414 Submission category : 7. Anti-seizure Medications / 7E. Other Year : 2024 Submission ID : 1209 Source : www.aesnet.org Presentation date : 12/8/2024 12:00:00 AM P … ucation arrow_drop_down AES Learn Resident Courses Epilepsy and Neurophysiology Fellowship Match Membership arrow_drop_down Become a Member Get Involved In Memoriam Directory (Members Only) Give arrow_drop_down Make a Gift Planned Giving Your Dollars at Work Targeted Funds Corporate Support About arrow_drop_down About AES Publications & Reports Press Room Reach Members Epilepsy Leadership Council Contact AES arrow_upward Back to top Terms of Use Disclosure P
Dr. Stephen Wright, former CMO of GW Pharma and lead developer of Epidiolex, joins Bloom Science Clinical Advisory Board, alongside clinical advisors Jacqueline French, MD and Eric Kossoff, MD. | Bloom Science, Inc. LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at
Understanding Algal Blooms: State of the Science Conference | SENR Skip to main content The Ohio State University Help BuckeyeLink Map Find People Webmail Search Ohio State CFAES COVID-19 Resources: Safe and Healthy Buckeyes | COVID-19 Hub | CFAES Calendar --> CFAES Give Today SENR SENR https://senr.osu.edu School of Environment and Natural Resources Search form Search Menu Home Future Students Explore SENR Majors Visit Personalized Virtual and In-Person Visits Admissions Process New First Year Students Transfer Student Regional Campus Student … raduate Research Undergraduate Research Spotlights Honors Graduation Graduation Application Form Money Matters Current Scholarship Opportunites Scholarship Spotlights Student Organizations ENR Stone Lab Experience Student Leadership Opportunities Peer Leaders Ambassadors Graduate Courses Programs Research Degrees Professional Masters (MENR) Research Areas Certificates Dual and Combined Degrees Graduate Minors Environment and Natural Resources Soil Science Rural and Environmen … Staff Extension Staff Extension Resources Directory Graduate Students Ohio Sea Grant and Stone Lab Emeritus & Former Faculty Associate Professors Assistant Professor About Us Courses Our Impact News More 2025 News More 2024 News More 2023 News More 2022 News More 2021 News More 2020 News Events Calendar Past Events 2026 Student Research Symposium Spring 2026 SENR Speaker Series Multimedia Follow Us on Social Media Photo Gallery Extension Resources Directory SENR at Woost … eople TWEL Opportunities TWEL Current Research TWEL Completed Projects Ohio Sea Grant & Stone Lab Sentinel Sites for Soil Change Extension/Outreach Agriculture, Food & Society Ohio Farm Trends Children & Youth Community, Environment & Development Environmental Professionals Network Forestry Building Ohio State Forest Operations & Products Invasive Species Ohio Certified Volunteer Naturalist Ponds, Fisheries, and Aquatic Management Aquatic Invasive Species … ovation Center Why the AIC? Our Services The Team Resources Contact Us Ohio Sea Grant Alumni About ENRAS ENRAS Constitution Executive Council Executive Committees Membership in ENRAS Become a ENRAS Sustaining Member Honorary 100 Membership Testimonial Newsletters Archived Newsletters HISTORY OF THE HONORARY 100 Contact ENRAS enr@work Calendar Pas
NCCOS-Supported Workshop Helps Strengthen Future Harmful Algal Bloom Response - NCCOS - National Centers for Coastal Ocean Science Skip to content An official website of the United States government. Here's how you know we're official. Official websites use .gov A .gov website belongs to an official government organization in the United States. Secure .gov websites use HTTPS A lock or https:// means you’ve safely connected to the .gov website. Share sensitive information only on official, secure websites. The U.S. Government is closed. This site will not be updated; however NOAA websites and s
Christopher Reyes - BIO Investment & Growth Summit 2026 Skip To Main Content February 16-17, 2027 | Miami Beach HOME ABOUT Show submenu for: ABOUT EVENT OVERVIEW WHY ATTEND? FAQS SHARE ON SOCIAL MEDIA CONTACT US SCHEDULE PROGRAM Show submenu for: PROGRAM PROGRAM SPEAKERS ADVISORY COMMITTEE COMPANY PRESENTATIONS PRESENTING COMPANIES BIO Partnering™ Show submenu for: BIO Partnering™ BIO PARTNERING™ PARTICIPATING COMPANIES PARTICIPATING INVESTORS PARTNERING WEBINARS DOWNLOAD THE APP LOG IN TO BIO PARTNERING SPONSOR Show submenu for: SPONSOR Become a Sponsor 2026 Sponsors SEARCH More Show mor
Bloom Science Appoints Medicine Development Expert Dr. Stephen Wright to Clinical Advisory Board - Bloom Science Science & Pipeline Patients People News & Resources Careers Contact Us Bloom Science Appoints Medicine Development Expert Dr. Stephen Wright to Clinical Advisory Board SAN DIEGO, Calif., January 4, 2023 — Dr. Stephen Wright joins Bloom Science, Inc., a clinical-stage biotechnology company developing novel medicines for neurological diseases and conditions, as a senior scientific and medical advisor alongside clinical advisors Jacqueline French, MD and Eric Kossoff, M … he clinic. Bloom medical advisor Dr. Kossoff is director of the Child Neurology Residency Program and a professor of neurology at Johns Hopkins Medicine. His expertise and research is in seizures and epilepsy, Ketogenic diet and Atkins diet for children and adults, infantile spasms, and Sturge-Weber syndrome. ABOUT BLOOM SCIENCE Bloom Science is a clinical-stage biotechnology company on a mission to bring transformative live biotherapeutic products (LBPs) to underserved patie
135 Capital - 2026 Investor Profile, Portfolio & Team - Tracxn JavaScript is disabled in your browser. enable it to enjoy the full features of Tracxn. Your browser was unable to load all of Tracxn resources. They may have been blocked by your firewall, proxy or browser configuration. Press Ctrl+F5 or Ctrl+Shift+R to have your browser try again and if that doesn't work, click here to retry or mail us at [email protected] Internal Server Error Toggle navigation Customers Investment Industry Venture Capital Funds Private Equity Funds Accelerators & Incubators Investment Banks Corporates … $12M Employee Count : 17 as on May 31, 2026 Investors : Bayer , ALS Investment Fund and 7 Other s Latest Funding Round : Grant (prize money), Apr 17, 2025 , $ ***** Highlight : Editors' Pick 2 . Aegiq Provider of quantum photonics hardware for communications. It develops satellite and fibre-based quantum key distribution technology for cybersecurity applications. It also develops a photonic platform that entangles quantum computing nodes, and enables quantum resource di … l as drug targets genetically linked to the disease using machine learning. The application of this technology is in diagnostics, pharma, and Doctors & Clinics. Key facts about Biotx Founded Year : 2017 Location : Berlin ( Germany ) Stage : Seed Employee Count : 16 as on May 31, 2026 Investors : Johnson & Johnson Innovation , JLABS and 8 Other s Latest Funding Round : Grant (prize money), Dec 09, 2020 , $ ***** Team profile of 135 Capital 135 Capital has a team of 1 membe
ALS Investment Fund | Portfolio, Investments & AUM | Caplight NEW Caplight raises a $16M Series A, led by BlackRock and Fin Capital → Products Solutions Resources Log in Book a demo Investors ALS Investment Fund ALS Investment Fund Amsterdam, North Holland alsinvestmentfund.com Overview A patient-led and patient-centric venture philanthropy fund with a single focus on investing in companies developing therapeutics and diagnostics for Amyotrophic Lateral Sclerosis (ALS). It was founded by ALS patients for ALS patients, and all returns on investments are re-invested to support further resear … and funding raised over time. Unlock full analytics FAQ Where is ALS Investment Fund based? When was ALS Investment Fund founded? How many portfolio companies does ALS Investment Fund have? What are some companies in ALS Investment Fund's portfolio? What was ALS Investment Fund's most recent investment? What sectors does ALS Investment Fund focus on? What company stages does ALS Investment Fund focus on? Firmographic Details Headquarters Amsterdam, North Holland Yea
Bloom Science Sexuality Education Playbooks — GUSH Productions 0 Skip to Content About Work Services News Contact Legacy Films Support Us Open Menu Close Menu About Work Services News Contact Legacy Films Support Us Open Menu Close Menu About Work Services News Contact Legacy Films Support Us Bloom Science Sexuality Education Playbooks Bloom is modernizing sexuality education, helping it to become the empathy, safety, and biology education that it always should have been. https://www.bloomscience.org/ Distribution: Distributed Through School Networks Funding & Support: IDEO Innovatio
We want to extend a thank... - Obesity Action Coalition - OAC Facebook Log In Obesity Action Coalition - OAC's Post Obesity Action Coalition - OAC Verified account May 30 at 4:00 PM · Shared with Public We want to extend a thank you to Bloom Science for their support as a Patron level member of OAC's Corporate Council! Your partnership is key to helping OAC elevate lived experience, share educational resources and support individuals affected by obesity. #CorporateCouncil #OAC #ThankYou All reactions: 3 Like Comment
Bloom Science Case Study - OnTheMarcMedia About Our Team Testimonials Services Public Relations Crisis Management Additional Services Industries Results Broadcast Media Print/Digital Case Studies Insights Blog Resources After Deadline Podcast Get Started About Our Team Testimonials Services Public Relations Crisis Management Additional Services Industries Results Broadcast Media Print/Digital Case Studies Insights Blog Resources After Deadline Podcast Get Started Search: Bloom Science Case Study On The Marc Media launched a PR campaign that helped Bloom Science turn its complex “Keto” pill cli
BioCentury - Klompas steps down as Zymeworks’ COO, president This Edition ARTICLE | Management Tracks Klompas steps down as Zymeworks’ COO, president Plus: Bloom names Colón chair, Replay hires Balakumaran as CMO By Richard Guy, Biopharma Analyst, and Gunjan Ohri, Data Content Analyst May 18, 2023 7:20 PM UTC Neil Klompas will s t ep down as president and COO of Zymeworks Inc. (NASDAQ:ZYME) on June 30. Klompas joined the Vancouver, B.C.-based company in 2007 as CFO. No successor was announced. Bloom Science Inc. appointed Grace Colón chair. Colón was president and CEO of InCarda Therapeutics I
Privacy Policy - Bloom Science Science & Pipeline Patients People News & Resources Careers Contact Us Privacy Policy Effective Date: 25-04-2023 We are committed to protecting Your privacy. This Privacy Policy describes how We collect, use, store, share and protect the information collected through https://bloomscience.com/ (the “ Website ”). In this Privacy Policy, “We”, “Us”, and “Our” refer to Bloom Science. For more information about Us, see “Our Details” at the end of this Policy. This Privacy Policy is incorporated into and subject to Our Term … nditions. Please be advised that the practices described in this Privacy Policy apply only to information gathered online through the Website. This Privacy Policy applies where We are acting as a data controller with respect to the Personal Data of visitors, users, clients and customers (“You,” or “Your”); in other words, where We determine the purposes and means of the processing of that Personal Data. PLEASE READ THIS PRIVACY POLICY CAREFULLY because it affects Your rights … g of changes to these terms will mean You accept those changes. If We intend to apply the modifications or amendments to this Privacy Policy retroactively or to Personal Data already in Our possession, We will provide You with notice of the modifications or amendments. Contents Click below to jump to any section of this privacy policy Your Data Personal Data Data We Collect How We Collect Data Personal Data On Or From Social Media Use of Personal Data Retaining and Deleting P … ic information” such as time of access, date of access, software crash reports, application errors, session identification number, access times, and referring site addresses. Your search terms and search results. Other information regarding Your use of the Website. Back to table of contents 8 Use of Non-Personal Data We may disclose or share Non-Personal Data (or other information, other than Personal Data) in any other manner that We deem appropriate or necessary. Among othe … ctured, commonly used and machine-readable format. However, this right does not apply where it would adversely affect the rights and freedoms of others. Right to Complain to a Supervisory Authority . If You consider that Our processing of Your Personal Data infringes data protection laws, You have a legal right to lodge a complaint with a supervi
Bloom Science to Present Live at Biotech Showcase 2023 - Bloom Science Science & Pipeline Patients People News & Resources Careers Contact Us Bloom Science to Present Live at Biotech Showcase 2023 SAN DIEGO, Calif., December 17, 2022 — Bloom Science, Inc. founder & CEO Christopher Reyes, PhD presents live at Biotech Showcase™ 2023 on Tuesday January 10 at 2:45 p.m. PT. Biotech Showcase, produced by Demy-Colton and EBD Group, is an investor conference focused on driving advances in therapeutic development by providing a sophisticated networking platform for executives and in
bloomscience, Author at Bloom Science Science & Pipeline Patients People News & Resources Careers Contact Us Bloom Science Initiates Phase 1b Obesity Trial of BL-001, Advancing a Differentiated Approach Beyond GLP-1 by bloomscience | Mar 23, 2026 | Press Releases First patient dosed in Phase 1b randomized, placebo-controlled study evaluating safety, tolerability and weight loss over 12 weeks Market research indicates strong demand for ketogenic-metabolic approaches, including among adults with obesity who are not currently receiving treatment BL-001 positioned as a potential oral ket
Bloom Science Granted Exclusive Option to License Gut Microbiome-based Therapies for ALS, Other Neurological Disorders — Duke OTC Skip to main content Faculty & Innovators Industry & Partners New Ventures Digital Innovations Duke Capital Partners Students Translational Funds About About Us A Century of Innovation Team By The Numbers Invented at Duke Contact News Events Pipeline Technologies Resources Submit an Invention Innovate Login Search Search Site About About Us A Century of Innovation Team By The Numbers Invented at Duke Contact News Events Pipeline Technologies Resource … he Numbers Invented at Duke Contact News Events Pipeline Technologies Resources Submit an Invention Innovate Login Search Search Site Faculty & Innovators Industry & Partners New Ventures Digital Innovations Duke Capital Partners Students Translational Funds News Home › News › Bloom Science Granted Exclusive Option to License Gut Microbiome-based Therapies for ALS, Other Neurological Disorders Clinical Trials Digital Innovation Engineering Entrepreneurship Events Li … ail Address * Job Title * Affiliation * I'm interested in: (Click all that apply) New Technologies Resources News, Events, Funding Opportunities Topics of Interest Life Sciences Engineering/Physical Sciences Medical Devices Digital Innovations Subscriber consent I consent to having my subscriber engagement tracked and analyzed. By clicking submit I consent to receive email as stated by these terms. Submitting
Bloom Science, Inc. - Drug pipelines, Patents, Clinical trials - Synapse Products Data Feature Plans Request Demo Sign Up for Free Last update 08 May 2025 Bloom Science, Inc. Startups | Holding Company | 2018 | California, United States | 10-50 | www.bloomscience.com Startups | Holding Company | 2018 | California, United States | 10-50 | www.bloomscience.com Last update 08 May 2025 Overview Pipeline Deal Translational Medicine Profit Grant & Funding(NIH) Investment Financing Overview Tags Nervous System Diseases Endocrinology and Metabolic Disease Cardiovascular Diseases Live biotherapeuti … itions of over 360K organizations with Synapse. login or view full example data Grant & Funding(NIH) Access more than 2 million grant and funding information to elevate your research journey. login or view full example data Investment Gain insights on the latest company investments from start-ups to established corporations. login or view full example data Financing Unearth financing trends to validate and advance investment opportunities. login or view full example data
Bloom Science, Inc. - Drug pipelines, Patents, Clinical trials - Synapse Products Data Feature Plans Request Demo Sign Up for Free Last update 08 May 2025 Bloom Science, Inc. Startups | Holding Company | 2018 | California, United States | 10-50 | www.bloomscience.com Startups | Holding Company | 2018 | California, United States | 10-50 | www.bloomscience.com Last update 08 May 2025 Overview Pipeline Deal Translational Medicine Profit Grant & Funding(NIH) Investment Financing Overview Tags Nervous System Diseases Endocrinology and Metabolic Disease Cardiovascular Diseases Live biotherapeuti … itions of over 360K organizations with Synapse. login or view full example data Grant & Funding(NIH) Access more than 2 million grant and funding information to elevate your research journey. login or view full example data Investment Gain insights on the latest company investments from start-ups to established corporations. login or view full example data Financing Unearth financing trends to validate and advance investment opportunities. login or view full example data
Bloom Science Announces Positive Topline Data from a Phase 1 Clinical Trial - Microbiome Times Magazine Sign up to our Free Newsletter Contact Us Editorial Submission Search for: Human Health Finance Drug Database Login About Issue Archive Advertise Recruitment Marketing Bloom Science Announces Positive Topline Data from a Phase 1 Clinical Trial August 18, 2023 Microbiome Times Finance , Pharma & Human Health Bloom Science, Inc., a clinical-stage, central nervous system (CNS) company focused on discovering and developing breakthrough therapeutics that target the Gut-Brain Axis for neurolog
Bloom Science Granted Exclusive Option to License Microbiome-Based Technology for the Development of Novel Treatments for Multiple Neurological and Oncology Conditions - Microbiome Times Magazine Sign up to our Free Newsletter Contact Us Editorial Submission Search for: Human Health Finance Drug Database Login About Issue Archive Advertise Recruitment Marketing Bloom Science Granted Exclusive Option to License Microbiome-Based Technology for the Development of Novel Treatments for Multiple Neurological and Oncology Conditions January 15, 2020 Microbiome Times Pharma & Human Health Bloom Sc … te Akkermansia strains with the most beneficial activities and accelerate their application as potential therapeutics, ” said Dr. Valdivia, who will be joining Bloom as a scientific founder. The financial terms of the agreement have not been disclosed. Sign Up to Free Newsletter QIAGEN WEBINAR SERIES – REGISTER HERE NEW WHITEPAPER: ORAL DELIVERY OF LIVE BIOTHERAPEUTIC PRODUCTS: Editor’s Choice LACTIN-V: A Promising Live Biotherapeutic for Recurrent Bacterial Vagin
Bloom Science | MTEC MTEC Focus Areas Who we serve Solicitations Patents About Us Explore Join MTEC Log In Life Sciences / Companies Bloom Science Bloom Science is a clinical-stage biotech company dedicated to developing innovative therapies targeting the Gut-Brain Axis for neurological and metabolic disorders. Their proprietary platform, IrisRx™, enables the development of multi-functional therapeutics from gut microbes, aiming to treat conditions such as Dravet syndrome, epilepsy, ALS, and other neurodegenerative diseases. The company focuses on creating safe, effective, first-in-class thera
Bloom Science, Inc. - The Gut Has a Plan for Your Brain Breaking Bloom Science raises $12M Series A led by Leaps by Bayer BL-001: a once-daily live biotherapeutic, not a pill of chemistry Launched out of UCLA on an exclusive microbiome license Phase 1 showed safety, tolerability, and statistically significant weight loss One platform, three targets: seizures, obesity, ALS Bloom Science raises $12M Series A led by Leaps by Bayer BL-001: a once-daily live biotherapeutic, not a pill of chemistry Launched out of UCLA on an exclusive microbiome license Phase 1 showed safety, tolerability, and stati … tners. 2021 Closes a $12M Series A led by Leaps by Bayer and the ALS Investment Fund, with Apollo Health Ventures and Joyance. 2022 Profiled by Nature on harnessing the gut-immune-brain axis to treat disease. 2023 Reframes around "Revolutionizing Metabolic and Neurological Health," expanding BL-001 into obesity alongside Dravet syndrome. Now BL-001 in Phase 1 : safety, tolerability, and statistically significant weight loss reported. The proof Microbiome hype is cheap. Endpoi … by Bayer Bayer AG's impact-investing arm led the $12M Series A. ALS Investment Fund Co-led the round - a nod to Bloom's ALS ambitions, not just epilepsy. Apollo + Joyance Apollo Health Ventures and early backer Joyance Partners rounded out the syndicate. The mission Revolutionizing metabolic and neurological health. Bloom's stated aim is to unlock new therapeutic pathways for metabolic and neurological health by harnessing the gut-immune-brain axis. Stripped of the slogan, i
Bloom Science, Inc. Company Profile: Financials, Valuation, and Growth | PrivCo Sign In Create Free Account PrivCo Bloom Science, Inc. Bloom Science, Inc. San Diego, CA Watchlist Export About Financials People Deals Funding About Bloom Science, Inc. Company overview Bloom Science, Inc. is a privately-held biotechnology company focused on discovering, developing and commercializing live biotherapeutics to treat unmet neurological and inflammatory diseases. Bloom Science, Inc. was founded in 2018 by Christopher Reyes, Elaine Hsiao, and Raphael Valdivia. Bloom Science, Inc. headquarters are locat
Skip to content How It Works Pricing Blog Events Partners Search orgs, people, news, resources... ⌘K Sign In Get Started → Search organizations, people, news, resources, and content... / How It Works Pricing Blog Events Partners Sign In Get Started → Loading organizations... The OS for early-stage founders from day zero to raise. Subscribe Product How It Works Pricing Partners Resources Blog Events Contact Company About Privacy Terms © 2026 Startup Intros, Inc. San Francisco, CA · Made for Founders Bloom Science: Funding, Team & Investors | Startup Intros Home / Organizations / Bloom Scien … utional investors such as Social Starts, Apollo Health Ventures, ALS Investment Fund, and Leaps by Bayer. Bloom Science was officially established in 2018 by founding team members Christopher Reyes, Elaine Hsiao, and Raphael Valdivia. Financial History Bloom Science has raised $12.0M across 1 funding round. Raised $12.0M 1 funding round Frequently Asked Questions How much funding has Bloom Science raised? Bloom Science has raised $12.0M in total across 1 funding round. Financ … Lead Investors Other Investors Status Dec 1, 2021 $12M Series A ALS Investment Fund , Leaps BY Bayer Apollo Health Ventures , Joyance Partners Announced Recent News & Mentions Dec 1, 2021 Funding Bloom Science - Series A Deep Dive High-Level Overview Bloom Science is a San Diego-based clinical-stage biotechnology company developing live biotherapeutics that harness the gut microbiome to treat unmet needs in neurological and metabolic disorders.[1][2][3] It targets the gu … Bloom raised $12M in Series A funding led by Leaps by Bayer and ALS Investment Fund, fueling pipeline advancement.[1] Origin Story Bloom Science was founded by Christopher Reyes, PhD , its CEO, driven by a vision to exploit the gut-immune-brain axis for untreatable neurological and inflammatory diseases.[1] The company emerged from insights into the microbiome's role in modulating brain and immune functions, rethinking drug development through live biotherapeutics.[1][2] Ear … Science's investors? Bloom Science's investors include ALS Investment Fund, Leaps by Bayer, Apollo Health Ventures, Joyance Partners.
Bloom Science Launches to Develop Neuroprotective Epilepsy Treatments in Orphan Indications with Exclusive Technology License from UCLA - Bloom Science Science & Pipeline Patients People News & Resources Careers Contact Us Bloom Science Launches to Develop Neuroprotective Epilepsy Treatments in Orphan Indications with Exclusive Technology License from UCLA Study published in Cell demonstrates causal link between seizure susceptibility and the microbiome, identifies gut bacteria that confer anti-seizure effects Bloom Science, a biotechnology company accelerating the development of a n … lans for R&D activities up through filing an investigational new drug (IND) application for its live biotherapeutic product (LBP) with the U.S. FDA. In parallel with its therapeutic development activities, Bloom is also developing a medical food that leverages GRAS (generally regarded as safe) designation to establish safety, enabling the company to transition directly into a proof-of-concept trial in patients. About Bloom Science Bloom Science is a biotechnology co
bloomscience, Author at Bloom Science - Page 4 of 7 Science & Pipeline Patients People News & Resources Careers Contact Us Bloom Science to Present at 24th Annual Biotech in Europe Forum by bloomscience | Sep 25, 2024 | In the News SAN DIEGO, Calif., September 24, 2024 – Bloom Science, Inc., a clinical-stage biotech company focused on the development of novel therapies for metabolic and neurological disorders, today announced that its Chief Executive Officer, Christopher Reyes, Ph.D., will be presenting at the 24th Annual Biotech in Europe Forum being held September 25-26, 2024
Dr. Christopher Reyes, CEO of Bloom Science, interviewed by @microbiomepost | Bloom Science, Inc. LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, you agree
Christopher Reyes, Founder and CEO of Bloom Science, joins a panel of experts to explore the Science of the Gut-Brain Axis - Bloom Science Science & Pipeline Patients People News & Resources Careers Contact Us Christopher Reyes, Founder and CEO of Bloom Science, joins a panel of experts to explore the Science of the Gut-Brain Axis SAN DIEGO, Calif., August 5, 2024 — Bloom Science, Inc., a clinical-stage biotech company focused on the development of novel therapies for metabolic and neurological disorders, today announced that CEO Christopher Reyes will join a panel of entrepreneurs a
Eolo | Grace E. Colón, Ph.D. [email protected] Home About Science SANA Scientific Publications News Contact Home About Science SANA Scientific Publications News Contact Home About Science SANA Scientific Publications News Contact Home About Science SANA Scientific Publications News Contact Grace E. Colón, Ph.D. Advisor Dr. Colón has had a nearly 30-year career spanning biopharma, genomics, diagnostics, health care, digital health, synthetic biology, industrial biotechnology, venture capital, management consulting and entrepreneurship. Most recently, she co-founded Inaya Therapeutics, and
Press Releases – Page 2 – Accelerator Home About People Portfolio Press Contact Press Releases Accelerator Life Science Partners Mourns the Loss of Senior Advisor and Friend, Tadataka "Tachi" Yamada, M.D. SEATTLE, WA – August 5, 2021 – Accelerator Life Science Partners (“ALSP”), a leading early-stage life science accelerator and investment firm, today acknowledged the sudden passing of senior advisor and board member, Tadataka (Tachi) Yamada, M.D., who died unexpectedly at home on August 4, 2021. “We are saddened to share the news of Tachi’s unexpected passing,” said Thong Q. Le, C … dation (WRF), a non-profit organization founded in 1981 to support research and scholarship in Washington state, with a focus on life sciences and enabling technologies. Mr. Howell was instrumental in developing a number of innovative grant-making programs to support breakthrough, early-stage research developed within Washington state’s institutions. In 1994, Mr. Howell established the WRF’s venture investment arm, WRF Capital, which has become a critical investment par … an undisclosed amount. The transaction is the third exit from ALSP’s investment fund, Accelerator Life Science Partners I (ALSP I) in the last year. Lodo Therapeutics discovered and developed novel therapeutics to address undruggable targets by applying its proprietary platform to tap the vast collections of undiscovered molecules encoded in environmental microbial DNA. “ The Lodo Therapeutics metagenomic platform compliments Zymergen’s discovery efforts by expanding their na … y Editor Proniras Corporation Announces National Institute on Drug Abuse (NIDA) Grant Award to Pursue Treatment for Opioid Withdrawal SEATTLE, WA — September 17, 2020 —Proniras Corporation, a biotechnology company committed to the development of life saving therapeutic products, today announced that the company and its collaborator, Indiana University (IU) School of Medicine, have received a $12.3 million grant from the National Institute on Drug Abuse (NIDA) to support devel … lobal rights to tezampanel (LY-293,558) from Eli Lilly and Company in 2017. The grant, titled “AMPA-antagonism: A Novel Pharmacology for Launching Recovery from Opioid Addiction,” will initially support the laboratory characterization of tezampanel in the context of various preclinical models of opioid withdrawal and in combination with opioid an
JavaScript is disabled In order to continue, we need to verify that you're not a robot. This requires JavaScript. Enable JavaScript and then reload the page.
Grace E. Colón - BIO and MIT | Biotech Showcase Speaker You need to enable JavaScript to run this app. The premier investor event January 11–13, 2027 | San Francisco, CA January 19–20, 2027 | Digital Partnering Home home About the event expand_more Biotech Showcase Get event brochure Who attends Attend expand_more Registration Options Present expand_more Company Presentation Options Presenter Resource Center Program expand_more Program Highlights 2026 Agenda 2026 Speakers partneringONE expand_more Partnering Partnering Upgrades Sponsors expand_more Sponsorship Brochure Sponsors Plan & Prep
I AM BIO I AM BIO What We Know About the Microbiome (REDUX) Episode Summary The gut microbiome, which consists of trillions of bacteria, viruses, and fungi, plays a crucial role in our health. However, there is still much to learn about this complex ecosystem. On this episode we talk with experts who tell us where the science is—how much we know, and how much we don’t. Two companies, Bloom Science and Seres Therapeutics, are leveraging the microbiome to develop new therapeutics. The potential of the microbiome is vast, and further research and technological advancements will continue to unlock … which was founded by Jennifer Doudna. Doudna, as you may know, shared the Nobel Prize in Chemistry for discovering the tool CRISPR/Cas9, [00:02:30] which is essentially genetic scissors. Later, we talk with Spencer about the fascinating application of CRISPR to the study of the microbiome. But first, Spencer gives us a crash course on the microbiome. Spencer Diamond: Microbiomes are extremely important for our health. We've correlated a lot of human diseases and conditions to … out the research around discovering how the microbiome functions and how we can apply what we learn to potentially improve our health and the environment. Our next [00:12:00] guest heads a company that is already developing therapeutic approaches based on microbiome science. Christopher Reyes: My name is Christopher Reyes. I'm CEO and co-founder of Bloom Science. Theresa Brady: At Bloom Science, instead of focusing on a faulty or unhealthy microbiome, they're discovering what
Client Challenge JavaScript is disabled in your browser. Please enable JavaScript to proceed. A required part of this site couldn’t load. This may be due to a browser extension, network issues, or browser settings. Please check your connection, disable any ad blockers, or try using a different browser.
Bloom Science - Products, Competitors, Financials, Employees, Headquarters Locations Technology Vendors Recent Research Newsletter Media Support Login Who We Serve Function Corporate Strategy Corporate Venture Capital Venture Capital IT Corporate Innovation How VCs Use CB Insights Go to the video gallery → Industries Consumer & Retail Tech Insurance Healthcare Industrials Financial Services Professional Services Professional Services Learn More → Success Stories How We Help Understand Tech Markets Anticipate Competitor Strategy Determine Tech Strategy Connect with Tech Vendors & Partne … generating data. Everything else follows from that. Dec 2, 2025 ALS Investment Fund closes third fund to finance innovation for neurodegenerative disease Mar 12, 2025 Asceletis’ muscle-preserving weight loss therapy sustains 40-day half-life Mar 10, 2025 Novo Nordisk’s stock drops despite CagriSema hitting goal of Phase III trial Mar 7, 2025 Bloom Science Demonstrates Durable Weight Loss in Overweight Individuals in Phase 1 Trial of BL-001 Learn more by requesting a demo Blo … Bloom Science? Investors of Bloom Science include Social Starts, ALS Investment Fund, Leaps by Bayer, Apollo Health Ventures, University of California Los Angeles and 5 more. Loading... Loading... 498 Seventh Avenue 12th floor New York, NY 10018 [email protected] 212 292 3148 Follow Us On Social About About Us Upcoming Webinars Contact Us How We Help Understand Tech Markets Anticipate Competitor Strategy Create Tech Strategy Connect with Tech Vendors Digital Transformation
Bloom Science Names Top Biotechnology Executive, Dr. Grace E. Colón, Board Chair Accessibility Statement Skip Navigation Resources Investor Relations Journalists Agencies Client Login Send a Release News Products Contact Search Search When typing in this field, a list of search results will appear and be automatically updated as you type. Searching for your content... No results found. Please change your search terms and try again. News in Focus Browse News Releases All News Releases All Public Company English-only News Releases Overview Multimedia Gallery All Multimedia All Photos All Videos … tform Login ProfNet Data Privacy Do not sell or share my personal information : Submit via [email protected] Call Privacy toll-free: 877-297-8921 Contact PR Newswire Products About My Services All News Releases Platform Login ProfNet Call PR Newswire at 888-776-0942 Terms of Use Privacy Policy Information Security Policy Site Map RSS Cookies Copyright © 2026 Cision US Inc. --> -->
Bloom Science Careers, Perks + Culture | Built In Companies Jobs Articles Can't find your company? Create a company profile. View All Jobs Join Log In For Employers Companies Bloom Science Teams Bloom Science Save Saved San Diego 6 Total Employees View Website Overview Jobs Offices Is This Your Company? Claim Profile Biotech Bloom Science is a platform Biotechnology company discovering and developing revolutionary new drugs. Bloom Science Offices OnSite Workspace Employees work from physical offices. Typical time on-site: San Diego, California, USA Companies Jobs Tracker Articles More Joi
Bloom Science - 2026 Company Profile, Team, Funding & Competitors - Tracxn JavaScript is disabled in your browser. enable it to enjoy the full features of Tracxn. Your browser was unable to load all of Tracxn resources. They may have been blocked by your firewall, proxy or browser configuration. Press Ctrl+F5 or Ctrl+Shift+R to have your browser try again and if that doesn't work, click here to retry or mail us at [email protected] Internal Server Error Toggle navigation Customers Investment Industry Venture Capital Funds Private Equity Funds Accelerators & Incubators Investment Banks … nited States Stage Series A Total Funding $12M in 5 rounds Latest Funding Round Grant (prize money), Apr 17, 2025 , $***** Investors Bayer & 8 more Ranked 436 th among 2961 active competitors Employee Count 17 as on Apr 30, 2026 Similar Companies Jazz Pharmaceuticals & 723 more View Bloom Science's full profile Sign up to download Bloom Science's company profile Sign Up for Free Bloom Science's funding and investors Bloom Science has raised a total fund … . Its first funding round was on May 24, 2018 . Its latest funding round was a Grant (prize money) round on Apr 17, 2025 for $ ***** . 1 investor participated in its latest round. Bloom Science has 9 institutional investor s . Here is the list of recent funding rounds of Bloom Science : Filter this list Date of Funding Funding Amount Round Name Post-Money Valuation Revenue Multiple Lead Investors Other Investors Apr 17, 2025 5972999 Grant (prize money) 3641487 4896216 434161 … 972999 Grant (prize money) 3641487 4896216 4341615 5825852 Sep 25, 2024 5285941 Grant (prize money) 6080223 3041452 7771408 HHS Dec 09, 2021 4847755 Series A 4357266 6941470 Bayer Apollo Health Ventures & 2 more Access funding benchmarks and valuations. Sign up today! View details of Bloom Science 's funding rounds and investors Bloom Science's founders and board of directors Founder? Claim Profile The founders of Bloom Science are Tony Colasin and Christopher R … veloper of therapies to treat neurological diseases $12M Bayer , ALS Investment Fund & 7 others 53/100 Get insights and benchmarks for competitors of 2M+ companies! Sign up today! Looking for more details on Bloom Science 's competitors? Click here to see the top ones Bloom Science's Investments and acquisitions Bloom Science has ma
Bloom Science’s Live Biotherapeutic BL-001 achieves significant weight loss in Phase 1 trial | MicrobiomePost Skip to content Join Sign In Topics Close Topics Open Topics Scientific News Allergology Cardiology Dentistry Dermatology Endocrinology Gastroenterology Geriatrics Gynecology Infectiology Immunology Nephrology Neuroscience Nutrition Oncology Ophthalmology See all scientific news Industry news New study shows Bimuno® GOS supports gut barrier integrity and immune health in athletes Gut bacteria may shape colon cell identity and protect against disease High sugar may promote severe fatty … yndrome, a rare developmental and epileptic encephalopathy (DEE). With its dual application in weight management and neurological disorders, BL-001 could emerge as a first-in-class, patient-friendly therapeutic alternative to traditional treatments. Breakthrough in obesity treatment: significant and sustained weight loss observed The Phase 1 trial, a randomized, double-blind, placebo-controlled study, evaluated the safety, tolerability, and pharmacokinetics (PK) and pharmacod … BL-001 in both obesity and Dravet Syndrome in 2026, reinforcing the drug’s dual application in metabolic and neurological conditions. A Disruptive new player in the obesity and neurology therapeutics landscape With current obesity treatments often relying on GLP-1 receptor agonists, such as semaglutide, there is a growing demand for alternative mechanisms with fewer side effects and improved patient adherence. BL-001’s natural, microbiome-based approach could offer a compleme
News & Media - Bloom Science Science & Pipeline Patients People News & Resources Careers Contact Us News and Media Press Releases Bloom Science Initiates Phase 1b Obesity Trial of BL-001, Advancing a Differentiated Approach Beyond GLP-1 Press Releases First patient dosed in Phase 1b randomized, placebo-controlled study evaluating safety, tolerability and weight loss over 12 weeks Market research indicates strong demand for ketogenic-metabolic... read more Bloom Science to Participate in Keystone Symposia on Obesity Therapeutics and Microbiome Revolution Symposium In the News SAN
Scientists Unlock Secrets of Gut Bacteria Linked to Heart Health | Duke University School of Medicine Skip to main content Utility Faculty Directory Contact Us Give Search Menu Close Main navigation About Us toggle sub nav items Leadership and Administration Facts & Figures History Named Professorships Faculty Resources Staff Resources Duke In Durham Alumni Giving Anatomical Gifts Program Calendar of Events Contact Us Education toggle sub nav items Health Professions Education Programs Biomedical Graduate Education Programs Biomedical PhD Programs Graduate Certificate & Training Progra … es of Health awards AI142376 and DK110496, the American Heart Association and a fellowship from the Natural Sciences and Engineering Research Council of Canada. Share Related News Study reveals first drug-like molecules that control key cellular signaling proteins PhD candidate discovers a hidden way that a fungal pathogen may resist treatment New study reveals ‘droplet’ mechanism behind key drug targets How songbirds learn to sing, one brain connection at
I am BIO Podcast explores the potential of the human microbiome - Bio.News Skip to content About Contact Bio.News Homepage Health Federal Policy State Policy Biosecurity International BIO’s View BIO Events Bio.News Homepage Health Federal Policy State Policy Biosecurity International BIO’s View BIO Events I am BIO Podcast explores the potential of the human microbiome March 13, 2024 / Health , Latest News / By Bio.News Staff Facebook Twitter/X Linkedin The human microbiome is a frontier charged with the potential to revolutionize health and medicine. The latest episode of the I am
Live Biotherapeutic Product Archives - Page 3 of 5 - Bloom Science Science & Pipeline Patients People News & Resources Careers Contact Us Bloom CEO Christopher Reyes, PhD Patriciates on IamBIO podcast Focused on Exploring the Science of the Microbiome by bloomscience | Feb 5, 2025 | In the News SAN DIEGO, Calif., March 12, 2024 — The gut microbiome plays a crucial role in our health. However, there is still much to learn about this complex ecosystem. In today’s IamBIO episode, Bloom’s CEO Chris Reyes joins other experts who tell us where the science is—how much we know, and how
Holy shit! Mental health and the gut (part 2 with Bloom Science) PsyMed Ventures Newsletter Subscribe Sign in Holy shit! Mental health and the gut (part 2 with Bloom Science) Business Trip by PsyMed Ventures, a podcast exploring the future of mental health & wellness PsyMed Ventures Sep 28, 2023 1 Share Welcome back to Business Trip by PsyMed Ventures, a podcast exploring the future of mental health & wellness! 🍄 We continue our 2-part series on microbial therapeutics for mental health with Dr. Christopher Reyes , biophysicist, serial entrepreneur, and founder of Bloom Science . Dr. R
Bloom Science on Harnessing the Gut-Brain Axis to Treat Neurological Disorders | VibeCast Episode 33 | Christopher Reyes, PhD LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to j
Bloom CEO Christopher Reyes, PhD Patriciates on IamBIO podcast Focused on Exploring the Science of the Microbiome - Bloom Science Science & Pipeline Patients People News & Resources Careers Contact Us Bloom CEO Christopher Reyes, PhD Patriciates on IamBIO podcast Focused on Exploring the Science of the Microbiome SAN DIEGO, Calif., March 12, 2024 — The gut microbiome plays a crucial role in our health. However, there is still much to learn about this complex ecosystem. In today’s IamBIO episode, Bloom’s CEO Chris Reyes joins other experts who tell us where the science is—how mu
Science - Bloom Science Science & Pipeline Patients People News & Resources Careers Contact Us Science Unlocking new therapeutic pathways for metabolic and neurological health Deep Pipeline of Novel Therapeutic Opportunities At Bloom Science, we are taking a fundamentally different approach to developing medicines by harnessing our deep knowledge about how the gut microbiome modulates key processes in metabolism, the immune system, nervous system and brain. Our programs and research areas include: Obesity and Metabolic syndromes Dravet syndrome and Developmental Epileptic Encephalopa
Science - Bloom Science Science & Pipeline Patients People News & Resources Careers Contact Us Science Unlocking new therapeutic pathways for metabolic and neurological health Deep Pipeline of Novel Therapeutic Opportunities At Bloom Science, we are taking a fundamentally different approach to developing medicines by harnessing our deep knowledge about how the gut microbiome modulates key processes in metabolism, the immune system, nervous system and brain. Our programs and research areas include: Obesity and Metabolic syndromes Dravet syndrome and Developmental Epileptic Encephalopa
�PNG IHDR`v�� gAMA�� �a IiCCPsRGB IEC61966-2.1H��SwX��>��eVB��l�"#��Y��a�@Ņ� V�HUĂ� H���(�gA��Z�U\8� ܧ�}z�����������y��&��j9R� ة��آ ���(G$@�`U�R,����@".���Y�2G��v�X�@`��B,� 8C � L�0ҿ�_p��H�˕͗K�3���w����!��l�Ba)f �"���#H�L� ����8?������f�l��Ţ�k�o">!�����N���_���p��u�k�[�Vh��]3� �Z �z��y8�@ ��P� �3�o��~��@ ��z�q�@������qanv�R���B1n��#�Dž��)��4�\,��X��P"M�y�R�D!ɕ��2� �� �w ��O�N���l�~��X�v@~�-� �g42y�����@+͗����\��L�D��*�A ����� ��aD@ $� �i�L&�m������ �����O�����:ň�L �$R��J5e?���2B���Qͩ����:�ZIm�vP/S��4u�%͛Cˤ-��Кigi�h/
Bloom Science Initiates Phase 1b Obesity Trial of BL-001, Advancing a Differentiated Approach Beyond GLP-1 - Bloom Science Science & Pipeline Patients People News & Resources Careers Contact Us Bloom Science Initiates Phase 1b Obesity Trial of BL-001, Advancing a Differentiated Approach Beyond GLP-1 First patient dosed in Phase 1b randomized, placebo-controlled study evaluating safety, tolerability and weight loss over 12 weeks Market research indicates strong demand for ketogenic-metabolic approaches, including among adults with obesity who are not currently receiving treatment BL-0
Homepage - Bloom Science Science & Pipeline Patients People News & Resources Careers Contact Us Revolutionizing Metabolic and Neurological Health The Power of the Gut-Brain Axis Our lead program, BL-001, is a live biotherapeutic product reverse engineered to replicate the ketogenic diet’s clinical efficacy. BL-001 has demonstrated proof of mechanism and has been observed to be safe and tolerable, with Bloom planning Phase 2 clinical trials in both obesity and Dravet syndrome. The IrisRx™ discovery platform powers Bloom’s pipeline by integrating cutting-edge science and a proprietary
Join Us - Bloom Science Science & Pipeline Patients People News & Resources Careers Contact Us Join Our Team Why Bloom At Bloom Science we balance fun with the serious business of changing lives. We have a values-driven culture that is built from the ground up. We empower our team members to treat every clinical trial like a patient’s life depends on it – because it does. Our leaders are in the trenches with you – committed to advancing science and moving mountains for a potentially transformational approach to medicine. Our Core Values Relentless curiosity: We are scientists
Elaine Yih-Nien Hsiao - Life Sciences Visionary - Los Angeles Times Advertisement News Home Page California Election 2024 Housing & Homelessness Politics Science & Medicine World & Nation Business Artificial Intelligence Autos Jobs, Labor & Workplace Real Estate Technology and the Internet California California Politics Earthquakes Education Housing & Homelessness L.A. Influential L.A. Politics Mental Health Climate & Environment Climate Change Water & Drought Entertainment & Arts Arts Books Stand-Up Comedy Hollywood Inc. The Envelope (Awards) Movies Music Telev … Healthy Living Higher Education Philanthropy Sections Show Search Search Query Submit Search Business by LA Times Studios AEROSPACE & DEFENSE ENTERTAINMENT LEGAL BANKING & FINANCE BEAUTY & FASHION COMMERCIAL REAL ESTATE CONSUMER ATTORNEYS LIFE SCIENCE ORANGE COUNTY PEOPLE & CULTURE C-SUITE INSPIRATIONAL WOMEN OC INSPIRATIONAL WOMEN NOMINATE ALL MAGAZINES >> More LA TIMES STUDIOS Learn more Content produced by LA Times Studios is developed from press r … nd Bloom Science. She also serves as a scientific consultant for the Hypothesis Fund and an advisor to Holobiome. Her research has earned prestigious honors, including the Blavatnik National Award in Life Sciences and the Takeda Innovators in Science Award. A UCLA graduate, Hsiao continues to lead translational research that bridges the gap between basic microbiology and clinical interventions for behavioral and gastrointestinal health. LATEST HEALTH & SCIENCE UPDATES Mem
Careers - Bloom Science Science & Pipeline Patients People News & Resources Careers Contact Us Careers at Bloom Science Join our team to help transform the lives of patients with rare diseases. At Bloom Science we balance fun with the serious business of changing lives. We have a values-driven culture that is built from the ground up. We empower our team members to treat every clinical trial like a patient’s life depends on it – because it does. Our leaders are in the trenches with you – committed to advancing science and moving mountains for a potentially transformational approach t
Join Us - Bloom Science Science & Pipeline Patients People News & Resources Careers Contact Us Join Our Team Why Bloom At Bloom Science we balance fun with the serious business of changing lives. We have a values-driven culture that is built from the ground up. We empower our team members to treat every clinical trial like a patient’s life depends on it – because it does. Our leaders are in the trenches with you – committed to advancing science and moving mountains for a potentially transformational approach to medicine. Our Core Values Relentless curiosity: We are scientists
Careers - Bloom Science Science & Pipeline Patients People News & Resources Careers Contact Us Careers at Bloom Science Join our team to help transform the lives of patients with rare diseases. At Bloom Science we balance fun with the serious business of changing lives. We have a values-driven culture that is built from the ground up. We empower our team members to treat every clinical trial like a patient’s life depends on it – because it does. Our leaders are in the trenches with you – committed to advancing science and moving mountains for a potentially transformational approach t
Careers - Bloom Science Science & Pipeline Patients People News & Resources Careers Contact Us Careers at Bloom Science Join our team to help transform the lives of patients with rare diseases. At Bloom Science we balance fun with the serious business of changing lives. We have a values-driven culture that is built from the ground up. We empower our team members to treat every clinical trial like a patient’s life depends on it – because it does. Our leaders are in the trenches with you – committed to advancing science and moving mountains for a potentially transformational approach t
Bloom Science Raises $12M in Series A Financing – Funding SMEs Salta ai contenuti News News per Imprenditori Richiedi Info - - series A , venture capital funding Bloom Science Raises $12M in Series A Financing Pubblicato il 9 Dicembre 2021 da CashInvoice 09 Dic USA – Bloom Science , a San Diego, CA-based biotech company, closed a USD $12m Series A financing. The round was led by Leaps by Bayer, the impact investment arm of Bayer AG, and the ALS Investment Fund. Additional investors include Apollo Health Ventures, as well as existing investor, Joyance Partners. Led by Chri … ALS. The investment will enable Bloom to file an Investigational New Drug (IND) application for BL-001 in refractory epilepsy and advance into Phase I clinical trials, as well as further expand development of its platform and advance its research and talent acquisition. 09/12/2021 Questo elemento è stato inserito in series A , venture capital funding . Aggiungilo ai segnalibri . CashInvoice Cassini Systems Raises $20.5M in Growth Funding Authoritive Raises $5M in Seed
The ALS Association Awards Bloom Science to Develop Novel Gut Microbiota-based Therapies for Amyotrophic Lateral Sclerosis (ALS) - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Biotech Beach The ALS Association Awards Bloom Science to Develop Novel Gut Microbiota-based Therapies for Amyotrophic Lateral Sclerosis (ALS) March 17, 2020 | 2 min read Twitter LinkedIn Facebook Email Print Bloom Science, a biopharmaceutical company focused on the discovery and development of medicines tailored for in … individual patients living with neurological diseases, has received a $500,000 grant from The ALS Association. SAN DIEGO , March 17, 2020 /PRNewswire/ -- Bloom Science , a biopharmaceutical company focused on the discovery and development of medicines tailored for individual patients living with neurological diseases, has received a $500,000 grant from The ALS Association . Bloom is leveraging its GOLD platform (Genetically Optimized Living Drugs) in combination with strong … obiota, or the spectrum of bacteria that naturally populate the human gut. This grant is made available from the Association's Lawrence and Isabelle Barnett Drug Development Program. "What BL-001 attempts to do is to modify the microorganisms in the stomach to restore the GABA and glutamate levels that are disrupted in the brains of people living with ALS," said Kuldip Dave , Ph.D., vice president of research at The ALS Association. "It's a fascinating approach to using the b … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Bloom Science Launches from Exclusive UCLA Tech License - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search News Business Bloom Science Launches from Exclusive UCLA Tech License May 24, 2018 | 2 min read | Mark Terry Twitter LinkedIn Facebook Email Print San Diego-based Bloom Science launched to develop epilepsy treatments based on a new class of neuroprotective drugs. The company, whose research wa … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Bloom Science Launches to Develop Neuroprotective Epilepsy Treatments in Orphan Indications with Exclusive Technology License from UCLA - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Biotech Beach Bloom Science Launches to Develop Neuroprotective Epilepsy Treatments in Orphan Indications with Exclusive Technology License from UCLA May 24, 2018 | 4 min read Twitter LinkedIn Facebook Email Print Study published in Cell demonstrates causal link between seizure susceptibility and the microbiome, identif … lans for R&D activities up through filing an investigational new drug (IND) application for its live biotherapeutic product (LBP) with the U.S. FDA. In parallel with its therapeutic development activities, Bloom is also developing a medical food that leverages GRAS (generally regarded as safe) designation to establish safety, enabling the company to transition directly into a proof-of-concept trial in patients. About Bloom Science Bloom Science is a biotechnology company … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Bloom Science Announces Initiation of Microbiome Sample Collection Study in Subjects Implementing the Ketogenic Diet - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Biotech Bay Bloom Science Announces Initiation of Microbiome Sample Collection Study in Subjects Implementing the Ketogenic Diet October 4, 2018 | 1 min read Twitter LinkedIn Facebook Email Print Bloom, targeting rare epileptic syndromes with orally-delivered pharmaceutical compositions of specific combined strains of n … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Bloom Science Raises USD $12 Million in Series A Financing - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releas … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Biotech Beach Bloom Science Raises USD $12 Million in Series A Financing December 9, 2021 | 5 min read Twitter LinkedIn Facebook Email Print Bloom Science is developing novel engineered and rationally selected microbiome-based treatments for neurological and inflammatory diseases with initial programs in Drug Resistant … ps by Bayer, the impact investment arm of Bayer AG, and the ALS Investment Fund. Additional investors include Apollo Health Ventures, as well as existing investor, Joyance Partners. Bloom Science is developing innovative therapeutics for rare neurological diseases utilizing its novel drug discovery platform, IrisRx, that reverse translates clinical treatments to identify the compositional and functional microbiome building blocks. By focusing on the microbiome, the … nd novel approach," said Felix Von Coerper , managing partner of ALS Investment Fund. The investment will enable Bloom to file an Investigational New Drug (IND) application for BL-001 in refractory epilepsy and advance into Phase I clinical trials, as well as further expand development of its platform and advance its research and talent acquisition. About Bloom Science Bloom Science is a biotechnology company focused on discovering, developing and commercializing live biother … the Bloom Science website at https://www.bloomscience.com/ About ALS Investment Fund The ALS Investment Fund supports and finances biotech companies developing drugs for Amyotrophic Lateral Sclerosis (ALS). We invest globally but focus on Europe and the US. Being a disease-specific VC fund, we bring in-depth knowledge and a deep network in the sp
Bloom Science Granted Exclusive Option to License Microbiome-Based Technology for the Development of Novel Treatments for Multiple Neurological and Oncology Conditions - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Dr … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search News Business Bloom Science Granted Exclusive Option to License Microbiome-Based Technology for the Development of Novel Treatments for Multiple Neurological and Oncology Conditions January 15, 2020 | 2 min read Twitter LinkedIn Facebook Email Print Exclusive license option grants Bloom rights to intellect … te Akkermansia strains with the most beneficial activities and accelerate their application as potential therapeutics, " said Dr. Valdivia, who will be joining Bloom as a scientific founder. The financial terms of the agreement have not been disclosed. About Bloom Science Bloom Science, a private company, is developing transformational medicines that target diseases in neurology and oncology. Our discovery platform starts with positive clinical outcomes that elucidates … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Bloom Science Completes Enrollment in Phase 1 Trial of BL-001, a First-in-Class Therapy Being Developed for Dravet Syndrome - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Busin … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search News Drug Development Bloom Science Completes Enrollment in Phase 1 Trial of BL-001, a First-in-Class Therapy Being Developed for Dravet Syndrome April 25, 2023 | 6 min read Twitter LinkedIn Facebook Email Print Bloom Science, Inc., a clinical-stage, central nervous system (CNS) company focused on discover … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Bloom Science Collaborates with Cedars-Sinai Medical Center to Expand Microbiome Research and Discovery into Brain Cancer - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Busines … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search News Business Bloom Science Collaborates with Cedars-Sinai Medical Center to Expand Microbiome Research and Discovery into Brain Cancer December 10, 2019 | 2 min read Twitter LinkedIn Facebook Email Print Bloom Science, a biopharmaceutical company developing microbiome-derived therapeutics in multiple neur … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Bloom Science and Biose industrie Announce Agreement to Initiate Manufacture Development of Promising Epilepsy Therapy Drug - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Busin … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Biotech Beach Bloom Science and Biose industrie Announce Agreement to Initiate Manufacture Development of Promising Epilepsy Therapy Drug September 6, 2018 | 2 min read Twitter LinkedIn Facebook Email Print Bloom Science and Biose industrie announced today an agreement for the manufacture development of Bloom Science’s … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Bloom Science Names Top Biotechnology Executive, Dr. Grace E. Colón, Board Chair - Bloom Science Science & Pipeline Patients People News & Resources Careers Contact Us Bloom Science Names Top Biotechnology Executive, Dr. Grace E. Colón, Board Chair SAN DIEGO, May 17, 2023 – Bloom Science, Inc., a clinical-stage, central nervous system (CNS) company focused on discovering and developing breakthrough therapeutics that target the Gut-Brain Axis, today announced the appointment of Dr. Grace E. Colón as Chair of its Board of Directors, effectively immediately. A distinguished scientist an
Press Releases Archives - Bloom Science Science & Pipeline Patients People News & Resources Careers Contact Us Bloom Science Initiates Phase 1b Obesity Trial of BL-001, Advancing a Differentiated Approach Beyond GLP-1 by bloomscience | Mar 23, 2026 | Press Releases First patient dosed in Phase 1b randomized, placebo-controlled study evaluating safety, tolerability and weight loss over 12 weeks Market research indicates strong demand for ketogenic-metabolic approaches, including among adults with obesity who are not currently receiving treatment BL-001 positioned as a potential oral k
Bloom Science Raises USD $12 Million in Series A Financing Accessibility Statement Skip Navigation Resources Investor Relations Journalists Agencies Client Login Send a Release News Products Contact Search Search When typing in this field, a list of search results will appear and be automatically updated as you type. Searching for your content... No results found. Please change your search terms and try again. News in Focus Browse News Releases All News Releases All Public Company English-only News Releases Overview Multimedia Gallery All Multimedia All Photos All Videos Multimedia Gallery Ove … ps by Bayer, the impact investment arm of Bayer AG, and the ALS Investment Fund. Additional investors include Apollo Health Ventures, as well as existing investor, Joyance Partners. Continue Reading Bloom Science is developing novel engineered and rationally selected microbiome-based treatments for neurological and inflammatory diseases with initial programs in Drug Resistant Epilepsy and Amyotrophic Lateral Sclerosis (ALS) Christopher Reyes, PhD, CEO and Founder Bloom S … nd novel approach," said Felix Von Coerper , managing partner of ALS Investment Fund. The investment will enable Bloom to file an Investigational New Drug (IND) application for BL-001 in refractory epilepsy and advance into Phase I clinical trials, as well as further expand development of its platform and advance its research and talent acquisition. About Bloom Science Bloom Science is a biotechnology company focused on discovering, developing and commercializing live biother … the Bloom Science website at https://www.bloomscience.com/ About ALS Investment Fund The ALS Investment Fund supports and finances biotech companies developing drugs for Amyotrophic Lateral Sclerosis (ALS). We invest globally but focus on Europe and the US. Being a disease-specific VC fund, we bring in-depth knowledge and a deep network in the space. The portfolio companies we invest in are diversified, with multiple therapies and/or active programs in other, often larger, di … w.apollo.vc/ About Joyance Partners: Joyance Partners is a $20M venture capital fund focused on emerging technologies that can help individuals feel happier, healthier, calmer, more confident, and less anxious or subject to pain. Joyance Partners is directed by Managing Partner Mike Edelhart and Founding Partner William Lohse, who also oversee th
Bloom Science to Participate in Keystone Symposia on Obesity Therapeutics and Microbiome Revolution Symposium - Bloom Science Science & Pipeline Patients People News & Resources Careers Contact Us Bloom Science to Participate in Keystone Symposia on Obesity Therapeutics and Microbiome Revolution Symposium SAN DIEGO, Calif., January 23, 2026 – Bloom Science, Inc., a clinical-stage biotechnology company developing next-generation live biotherapeutic medicines targeting the gut-brain axis, today announced that members of its executive leadership team will participate in the upcomi
bloomscience, Author at Bloom Science - Page 5 of 7 Science & Pipeline Patients People News & Resources Careers Contact Us Bloom Science Names Top Biotechnology Executive, Dr. Grace E. Colón, Board Chair by bloomscience | May 17, 2023 | Press Releases SAN DIEGO, May 17, 2023 – Bloom Science, Inc., a clinical-stage, central nervous system (CNS) company focused on discovering and developing breakthrough therapeutics that target the Gut-Brain Axis, today announced the appointment of Dr. Grace E. Colón as Chair of its Board of Directors, effectively immediately. A distinguished scientist … he clinic. Bloom medical advisor Dr. Kossoff is director of the Child Neurology Residency Program and a professor of neurology at Johns Hopkins Medicine. His expertise and research is in seizures and epilepsy, Ketogenic diet and Atkins diet for children and adults, infantile spasms, and Sturge-Weber syndrome. ABOUT BLOOM SCIENCE Bloom Science is a clinical-stage biotechnology company on a mission to bring transformative live biotherapeutic products (LBPs) to underserved patie